RAS基因以外的阴性超选择：是转移性结直肠癌选择最佳维持治疗的关键工具吗？ - Suppr

Suppr

超能文献

Negative hyperselection beyond RAS: is a key tool for choosing the optimal maintenance treatment in metastatic colorectal cancer?

作者信息

Pericay Carles, Fernández-Plana Julen

机构信息

Medical Oncology Department, Hospital Universitari Mútua Terrassa (HUMT), Terrassa, Spain.

出版信息

J Gastrointest Oncol. 2024 Oct 31;15(5):2349-2352. doi: 10.21037/jgo-24-284. Epub 2024 Oct 29.

DOI:10.21037/jgo-24-284

PMID:39554573

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11565102/

Abstract

摘要

相似文献

Negative hyperselection beyond RAS: is a key tool for choosing the optimal maintenance treatment in metastatic colorectal cancer?RAS基因以外的阴性超选择：是转移性结直肠癌选择最佳维持治疗的关键工具吗？

J Gastrointest Oncol. 2024 Oct 31;15(5):2349-2352. doi: 10.21037/jgo-24-284. Epub 2024 Oct 29.

Negative Hyperselection of Resistance Mutations for Panitumumab Maintenance in RAS Wild-Type Metastatic Colorectal Cancer (PanaMa Phase II Trial, AIO KRK 0212).帕尼单抗维持治疗RAS野生型转移性结直肠癌中耐药突变的阴性超选择（帕尼单抗维持治疗转移性结直肠癌II期试验，AIO KRK 0212）

Clin Cancer Res. 2024 Apr 1;30(7):1256-1263. doi: 10.1158/1078-0432.CCR-23-3023.

The role of negative hyperselection in metastatic colorectal cancer.阴性超选择在转移性结直肠癌中的作用。

J Gastrointest Oncol. 2024 Oct 31;15(5):2353-2357. doi: 10.21037/jgo-24-376. Epub 2024 Oct 16.

The clinical effectiveness and cost-effectiveness of cetuximab (review of technology appraisal no. 176) and panitumumab (partial review of technology appraisal no. 240) for previously untreated metastatic colorectal cancer: a systematic review and economic evaluation.西妥昔单抗（技术评估报告第176号综述）和帕尼单抗（技术评估报告第240号部分综述）用于既往未治疗的转移性结直肠癌的临床疗效和成本效果：一项系统评价与经济学评估

Health Technol Assess. 2017 Jun;21(38):1-294. doi: 10.3310/hta21380.

Negative Hyperselection of Patients With and Wild-Type Metastatic Colorectal Cancer Who Received Panitumumab-Based Maintenance Therapy.伴有和野生型转移性结直肠癌患者接受帕尼单抗维持治疗的负性选择。

J Clin Oncol. 2019 Nov 20;37(33):3099-3110. doi: 10.1200/JCO.19.01254. Epub 2019 Sep 20.

The best strategy for RAS wild-type metastatic colorectal cancer patients in first-line treatment: A classic and Bayesian meta-analysis.一线治疗中 RAS 野生型转移性结直肠癌患者的最佳策略：经典荟萃分析与贝叶斯荟萃分析。

Crit Rev Oncol Hematol. 2018 May;125:69-77. doi: 10.1016/j.critrevonc.2018.03.003. Epub 2018 Mar 9.

The clinical effectiveness and cost-effectiveness of cetuximab (mono- or combination chemotherapy), bevacizumab (combination with non-oxaliplatin chemotherapy) and panitumumab (monotherapy) for the treatment of metastatic colorectal cancer after first-line chemotherapy (review of technology appraisal No.150 and part review of technology appraisal No. 118): a systematic review and economic model.西妥昔单抗（单药或联合化疗）、贝伐珠单抗（联合非奥沙利铂化疗）和帕尼单抗（单药治疗）用于一线化疗后转移性结直肠癌治疗的临床疗效和成本效果评价（技术评估 150 号报告的部分回顾和技术评估 118 号报告的综述）：系统评价和经济模型。

Health Technol Assess. 2013 Apr;17(14):1-237. doi: 10.3310/hta17140.

The prognostic role of HIF-1α and NF-κB expression in RAS wild-type metastatic colorectal cancer: A Turkish Oncology Group (TOG) study.缺氧诱导因子-1α（HIF-1α）和核因子-κB（NF-κB）表达在 RAS 野生型转移性结直肠癌中的预后作用：土耳其肿瘤学组（TOG）研究。

J Cancer Res Clin Oncol. 2023 Aug;149(10):6849-6856. doi: 10.1007/s00432-023-04628-y. Epub 2023 Feb 20.

Negative hyperselection of elderly patients with RAS and BRAF wild-type metastatic colorectal cancer receiving initial panitumumab plus FOLFOX or 5-FU/LV.初始接受帕尼单抗联合 FOLFOX 或 5-FU/LV 治疗的 RAS 和 BRAF 野生型转移性结直肠癌老年患者的负性选择。

Eur J Cancer. 2023 Dec;195:113396. doi: 10.1016/j.ejca.2023.113396. Epub 2023 Oct 20.

Impact of early tumor shrinkage and depth of response on the outcomes of panitumumab-based maintenance in patients with RAS wild-type metastatic colorectal cancer.基于帕尼单抗维持治疗 RAS 野生型转移性结直肠癌患者中早期肿瘤退缩和反应深度对结局的影响。

Eur J Cancer. 2021 Feb;144:31-40. doi: 10.1016/j.ejca.2020.11.017. Epub 2020 Dec 13.

本文引用的文献

Trifluridine-tipiracil plus bevacizumab versus trifluridine-tipiracil monotherapy for chemorefractory metastatic colorectal cancer: a systematic review and meta-analysis.替氟尿苷替匹嘧啶联合贝伐珠单抗对比替氟尿苷替匹嘧啶单药治疗化疗耐药转移性结直肠癌的系统评价和荟萃分析。

BMC Cancer. 2024 Jun 3;24(1):674. doi: 10.1186/s12885-024-12447-8.

Baseline ctDNA gene alterations as a biomarker of survival after panitumumab and chemotherapy in metastatic colorectal cancer.基线 ctDNA 基因突变作为转移性结直肠癌使用帕尼单抗和化疗后生存的生物标志物。

Nat Med. 2024 Mar;30(3):730-739. doi: 10.1038/s41591-023-02791-w. Epub 2024 Feb 12.

Clin Cancer Res. 2024 Apr 1;30(7):1256-1263. doi: 10.1158/1078-0432.CCR-23-3023.

Current Status of Angiogenesis Inhibitors as Second-Line Treatment for Unresectable Colorectal Cancer.血管生成抑制剂作为不可切除结直肠癌二线治疗的现状

Cancers (Basel). 2023 Sep 14;15(18):4564. doi: 10.3390/cancers15184564.

Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with metastatic colorectal cancer.泛亚地区适应的 ESMO 临床实践指南：转移性结直肠癌患者的诊断、治疗和随访。

ESMO Open. 2023 Jun;8(3):101558. doi: 10.1016/j.esmoop.2023.101558. Epub 2023 May 24.

Panitumumab vs Bevacizumab Added to Standard First-line Chemotherapy and Overall Survival Among Patients With RAS Wild-type, Left-Sided Metastatic Colorectal Cancer: A Randomized Clinical Trial.帕尼单抗联合贝伐珠单抗对比标准一线化疗方案联合贝伐珠单抗用于 RAS 野生型、左侧转移性结直肠癌患者的生存获益：一项随机临床试验。

JAMA. 2023 Apr 18;329(15):1271-1282. doi: 10.1001/jama.2023.4428.

Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.转移性结直肠癌：ESMO 诊断、治疗及随访临床实践指南

Ann Oncol. 2023 Jan;34(1):10-32. doi: 10.1016/j.annonc.2022.10.003. Epub 2022 Oct 25.

Treatment of Metastatic Colorectal Cancer: ASCO Guideline.转移性结直肠癌的治疗：ASCO 指南。

J Clin Oncol. 2023 Jan 20;41(3):678-700. doi: 10.1200/JCO.22.01690. Epub 2022 Oct 17.

Liquid biopsies to monitor and direct cancer treatment in colorectal cancer.液体活检在结直肠癌中监测和指导治疗的应用。

Br J Cancer. 2022 Aug;127(3):394-407. doi: 10.1038/s41416-022-01769-8. Epub 2022 Mar 9.

Panitumumab Plus Fluorouracil and Folinic Acid Versus Fluorouracil and Folinic Acid Alone as Maintenance Therapy in Wild-Type Metastatic Colorectal Cancer: The Randomized PANAMA Trial (AIO KRK 0212).帕尼单抗联合氟尿嘧啶和亚叶酸治疗与氟尿嘧啶和亚叶酸单独维持治疗野生型转移性结直肠癌：PANAMA 试验（AIO KRK 0212）的随机研究。

J Clin Oncol. 2022 Jan 1;40(1):72-82. doi: 10.1200/JCO.21.01332. Epub 2021 Sep 17.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验